文献速递肾小球疾病

成年或晚青春期起病的微小病变肾病综合征临床病程:病例系列

The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.
PubMed 文献 · Am J Kidney Dis · 2017-01-12

该回顾性病例系列分析了1985至2011年间10个中心收治的125例16岁及以上起病的微小病变肾病综合征患者,其中105例(84%)初始接受糖皮质激素治疗,92例(88%)在16周内达到缓解,中位缓解时间4周;57例(54%)复发,50例(40%)发生急性肾损伤,11例(9%)发生血栓,3例激素抵抗者进展至终末期肾病。

要点

  • 105例初始激素治疗者中92例(88%)在16周内缓解,中位缓解时间4周。
  • 57例(54%)初始激素治疗者出现至少一次复发,环磷酰胺使57%复发者获稳定缓解。
  • 50例(40%)发生急性肾损伤,11例(9%)发生血栓,3例激素抵抗者进展至终末期肾病。

核心结论

  • 绝大多数成年或晚青春期起病的微小病变肾病综合征患者接受糖皮质激素治疗并达到缓解,但许多患者出现复发;环磷酰胺使许多复发患者获得稳定缓解;急性肾损伤和其他并发症导致显著发病率;少数患者进展至终末期肾病,可由局灶节段性肾小球硬化解释。

研究设计与样本

  • 回顾性病例系列,纳入1985至2011年间10个参与中心病理记录中16岁及以上、新发肾病综合征且组织学诊断为微小病变肾病综合征的125例患者。

主要发现

  • 105例(84%)患者初始接受糖皮质激素治疗,其中92例(88%)在16周皮质激素治疗后达到缓解,中位缓解时间4(IQR 2-7)周。
  • 7例(6%)患者初始接受环磷酰胺联合或不联合糖皮质激素治疗,全部在中位4(IQR 3-11)周后达到缓解。
  • 13例(10%)患者未接受免疫抑制治疗即达到缓解。
  • 接受初始糖皮质激素治疗的57例(54%)患者观察到至少一次复发;二线环磷酰胺使57%的复发性微小病变肾病综合征患者获得稳定缓解。
  • 50例(40%)患者发生急性肾损伤,肾功能恢复几乎无例外;11例(9%)患者发生动脉或静脉血栓;末次随访时113例(90%)患者处于缓解且肾功能保留;3例激素抵抗的微小病变肾病综合征患者进展至终末期肾病,与重复活检上的局灶节段性肾小球硬化病变相关。

局限性

  • 回顾性设计。
  • 治疗方案不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few studies have examined the treatment and outcome of adult-onset minimal change nephrotic syndrome (MCNS). We retrospectively studied 125 patients who had MCNS with onset in either adulthood or late adolescence. Presenting characteristics, duration of initial treatment and response to treatment, relapse patterns, complications, and long-term outcome were studied. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: Patients with new-onset nephrotic syndrome 16 years or older and a histologic diagnosis of MCNS in 1985 to 2011 were identified from pathology records of 10 participating centers. OUTCOMES: Partial and complete remission, treatment resistance, relapse, complications, renal survival. RESULTS: Corticosteroids were given as initial treatment in 105 (84%) patients. After 16 weeks of corticosteroid treatment, 92 (88%) of these patients had reached remission. Median time to remission was 4 (IQR, 2-7) weeks. 7 (6%) patients initially received cyclophosphamide with or without corticosteroids, and all attained remission after a median of 4 (IQR, 3-11) weeks. 13 (10%) patients reached remission without immunosuppressive treatment. One or more relapses were observed in 57 (54%) patients who received initial corticosteroid treatment. Second-line cyclophosphamide resulted in stable remission in 57% of patients with relapsing MCNS. Acute kidney injury was observed in 50 (40%) patients. Recovery of kidney function occurred almost without exception. Arterial or venous thrombosis occurred in 11 (9%) patients. At the last follow-up, 113 (90%) patients were in remission and had preserved kidney function. 3 patients with steroid-resistant MCNS progressed to end-stage renal disease, which was associated with focal segmental glomerulosclerosis lesions on repeat biopsy. LIMITATIONS: Retrospective design, variable treatment protocols. CONCLUSIONS: The large majority of patients who had MCNS with onset in adulthood or late adolescence were treated with corticosteroids and reached remission, but many had relapses. Cyclophosphamide resulted in stable remission in many patients with relapses. Significant morbidity was observed due to acute kidney injury and other complications. Progression to end-stage renal disease occurred in a few patients and was explained by focal segmental glomerulosclerosis.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Maas RJ, Deegens JK, Beukhof JR, et al. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. Am J Kidney Dis. 2017. PMID: 28089478. doi:10.1053/j.ajkd.2016.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。